09:11 AM EDT, 08/14/2025 (MT Newswires) -- Eli Lilly ( LLY ) is collaborating with Superluminal Medicines to develop small-molecule therapeutics to treat cardiometabolic diseases and obesity, Superluminal Medicines said Thursday.

Superluminal Medicines said it may receive up to $1.3 billion from Eli Lilly ( LLY ), including upfront and near-term payments as well as an equity investment in the company, milestone-linked payments, and royalties on net sales.

Superluminal said it will use its platform to discover small-molecule therapeutics that target G protein-coupled receptors related to cardiometabolic diseases and obesity, while Lilly will get exclusive rights to develop and commercialize drug candidates.